Editor’s note: This story has been updated to reflect a new press release issued by Novo Nordisk that clarifies details around the primary endpoint of a semaglutide trial. Tuesday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the kidney outcomes trial, FLOW. The study compared injectable semaglutide 1.0 mg with placebo as an adjunct to the standard of care on kidney outcomes for prevention of progression of kidney impairment and risk of kidney and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease (CKD). The trial enrolled 3,533 people with typ…
